NBT Bank N A NY Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

NBT Bank N A NY lowered its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 44.2% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,392 shares of the medical research company's stock after selling 1,896 shares during the period. NBT Bank N A NY's holdings in IQVIA were worth $422,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. American National Bank & Trust purchased a new position in IQVIA during the first quarter worth about $26,000. ST Germain D J Co. Inc. increased its position in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the fourth quarter worth $39,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA during the fourth quarter worth $44,000. Finally, Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after acquiring an additional 85 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Barclays cut their target price on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen downgraded IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. lowered their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Finally, Redburn Partners set a $188.00 target price on shares of IQVIA in a research report on Friday, May 23rd. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

NYSE:IQV opened at $154.63 on Thursday. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a market cap of $26.75 billion, a price-to-earnings ratio of 21.07, a price-to-earnings-growth ratio of 1.69 and a beta of 1.28. The company's 50-day moving average is $147.79 and its two-hundred day moving average is $176.74. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter in the prior year, the firm posted $2.54 earnings per share. The company's quarterly revenue was up 2.5% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.